Off-the-Wall Higgs in the Universal Randall-Sundrum Model

We outline a consistent Randall-Sundrum (RS) framework in which a fundamental 5-dimensional Higgs doublet induces electroweak symmetry breaking (EWSB). In this framework of a warped Universal Extra Dimension, the lightest Kaluza-Klein (KK) mode of the bulk Higgs is tachyonic leading to a vacuum expectation value (vev) at the TeV scale. The consistency of this picture imposes a set of constraints on the parameters in the Higgs sector. A novel feature of our scenario is the emergence of an adjustable bulk profile for the Higgs vev. We also find a tower of non-tachyonic Higgs KK modes at the weak scale. We consider an interesting implementation of this ``Off-the-Wall Higgs'' mechanism where the 5-dimensional curvature-scalar coupling alone generates the tachyonic mode responsible for EWSB. In this case, additional relations among the parameters of the Higgs and gravitational sectors are established. We discuss the experimental signatures of the bulk Higgs in general, and those of the ``Gravity-Induced'' EWSB in particular.Comment: 27 pages, 4 figure

Towards a single-chip, implantable RFID system: is a single-cell radio possible?

We present an overview of progress towards single-chip RFID solutions. To date heterogeneous integration has been appropriate for non-biological systems. However, for in-vivo sensors and even drug delivery systems, a small form factor is required. We discuss fundamental limits on the size of the form factor, the effect of the antenna, and propose a unified single-chip RFID solution appropriate for a broad range of biomedical in-vivo device applications, both current and future. Fundamental issues regarding the possibility of single cell RF radios to interface with biological function are discussed

Effect of antilymphoma antibody, I-131_Lym_1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma

Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (RituxanO, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., South San Francisco, CA) or radiola * beled 90Y-ibritumomab (Zevaline, Biogen Idec Inc., Cambridge, MA) and I-131-tositumomab (Bexxaro; Glaxo Smith Kline, Research Triangle Park, NC), have proven to be effective therapy for non-Hodgkin's lymphoma (NHL), but also induce immediate and persistent decreases in normal peripheral blood lymphocytes (PBLs). Lym-1, a mAb that selectively targets malignant lymphocytes, also has induced therapeutic responses and prolonged survival in patients with NHL when labeled with iodine-131 (I-131). We have retrospectively examined its effect on PBLs in 41 NHL patients that had received I-131-Lym-1 therapy. Absolute lymphocyte counts (ALCs) were evaluated before and after the first and last I-131-Lym-1 infusion. Modest decreases in PBLs were observed in most of the patients. Using strict criteria to define recovery, time to recovery was determined for 19 patients, with the remainder censored because of insufficient follow-up (median follow up for censored patients: 22 days). Using Kaplan-Meier estimates, it would be predicted that 31 % of patients would recover by 28 days and that median time to recovery would be 44 days after the last I-131-Lym-1 infusion. No predictors were found for time to recovery, considering such factors as the administered Lym-1 or 13 '1 dose, spleen volume, or radiation doses to the body, marrow, or spleen. The data suggest that the effect of I-131-Lym-1 on ALC is the result of a nonspecific radiation effect, rather than a specific Lym-l mAb effect. The shorter time required for ALC recovery after I-131-Lym-1 when compared to that reportedfor anti-CD20 mAbs, whether radiolabeled or otherwise, is probably related to differing mechanisms for lymphocytotoxicity and lesser Lym-1 antigenic density on normal B-lymphocytes